EarningsQ2 2026 Earnings Report
MX:ALT1 Q2 2026 EPS Results
Actual EPS-$2.03
Consensus EPS-$2.30
Beat/MissBeat by +$0.27
One Year Ago EPS-$4.57
MX:ALT1 Q2 2026 Revenue Results
Actual Revenue$0.00
Expected Revenue$0.00
Beat/MissMet expectations
YoY Revenue Growth-100.00%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeBefore Open
Conference CallWednesday, August 12, 2026
MX:ALT1 Upcoming Earnings
Altimmune's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ALT1 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial clinical and operational momentum: initiation of a global Phase III in MASH, robust positive Phase II AUD data that met multiple registrational endpoints (including objective biomarker improvements and 9.1% weight loss), completed enrollment in ALD, and a strengthened balance sheet ($519M cash). Key positives notably outweigh near‑term risks, though important caveats remain — including higher operating expenses, GI-related tolerability signals under further review, a competitive MASH enrollment landscape, and the need to secure non-dilutive funding for a potential AUD Phase III (not covered by the current runway). Several pivotal readouts (RESTORE H2 2027, PERFORMA 52‑week in 2029) and regulatory engagements are upcoming and will be determinative for long-term value.Company Guidance
Initiation of PERFORMA Phase III in MASH
Global PERFORMA Phase III trial initiated and enrolling; ~300 sites planned (≈1/3 U.S., 2/3 ex-U.S.). Trial launched quickly (≈3 months after securing funding) with target enrollment window ~18–24 months and a 52-week biopsy readout expected in 2029.
Strong RECLAIM Phase II Results in AUD
RECLAIM met its primary endpoint: pemvidutide 2.4 mg showed a treatment difference of 1.45 fewer heavy drinking days per week versus placebo at week 24. Key secondary/regulatory endpoints: ~66% of pemvidutide patients achieved a 2-level WHO RDL reduction vs ~33% on placebo, and >2x the proportion of pemvi patients achieved 0 heavy drinking days vs placebo. Objective biomarker PEth and days abstinent both showed highly statistically significant improvements.
Weight Loss Benefit Observed in AUD Trial
Pemvidutide produced a meaningful body-weight reduction in RECLAIM: 9.1% weight loss versus placebo at 24 weeks, supporting potential dual benefits on weight and drinking behavior.
RESTORE (ALD) Enrollment Complete; Protocol Strengthened
RESTORE trial enrolled ~120 ALD patients and top-line data expected in H2 2027. Protocol amended to assess liver stiffness (LSM) hierarchically at week 48 then week 24 to better demonstrate longer-term liver benefit.
Financial Position and Runway
Company strengthened balance sheet, raising ≈$310M YTD (including $225M offering in April); cash on June 30, 2026 was $519M. Management states this cash runway funds operations through the PERFORMA Phase III 52‑week readout (expected 2029).
Progress Toward Regulatory Path for AUD
Management plans to request an End of Phase II meeting with FDA to discuss a pivotal AUD path; company believes 1 global pivotal trial may be sufficient per recent FDA guidance when supported by strong biomarkers (e.g., PEth) and validated endpoints.
Innovative Operational Features: AIM‑MASH Assist
PERFORMA will incorporate an AI-assisted digital pathology workflow (AIM‑MASH / PathAI) to propose scores, reduce variability and screen failures, and improve consistency of biopsy reads—first Phase III to include this approach for MASH.
Clinical Safety and Tolerability
Pemvidutide continued to demonstrate a generally consistent safety and tolerability profile across studies; no new safety signals called out in the top-line disclosures.
Commercial Opportunity in AUD and Liver Disease
Large addressable AUD population (~27M adults with AUD; ~12M moderate-to-severe) with low diagnosis/treatment rates (≈10% diagnosed; ~25% of diagnosed receive drug therapy). Management positions pemvidutide as a differentiated therapy with potential liver-directed benefit that could drive future uptake.
MX:ALT1 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed